Filters








55,368 Hits in 3.1 sec

plenary session 1: opening, keynotes and reviews

2007 Annals of Oncology  
in resistance to imatinib and eventually cause relapse of leukaemia.  ...  The 2-phenylaminopyrimidine derivative imatinib (Glivec) is a tyrosine kinase inhibitor (TKI) that interacts and inhibits ATP dependent activation of p210 bcr-abl , induces apoptosis and results in clearance  ...  low rate of cardiotoxicity suggesting that lapatinib has great potential for treating patients at an early stage of their disease where cardiac toxicity is perhaps of greatest concern. plenary session 1  ... 
doi:10.1093/annonc/mdm150 fatcat:ykovlz5uxzdsdfn3srzx5rlksi

Reading the Stories of Teaching and Learning—ISSOTL 2016 Opening Keynote

Karen Manarin
2017 Teaching & Learning Inquiry: The ISSOTL Journal  
This essay is based on the opening keynote for ISSOTL 2016: Telling the Stories of Teaching and Learning in Los Angeles, California.  ...  I argue that we should examine our unspoken assumptions about genre in SoTL and consider what elements of teaching and learning get left out because they are too hard to represent in our dominant genres  ...  Reading the stories of teaching and learning. Teaching & Learning Inquiry, 5(1). http://dx.doi.org/10.20343/teachlearninqu.5.1.13  ... 
doi:10.20343/5.1.13 fatcat:e4tc5uzu2vfuxmtp3wvsw6fqhy

Reading the Stories of Teaching and Learning—ISSOTL 2016 Opening Keynote

Karen Manarin
2017 Teaching & Learning Inquiry: The ISSOTL Journal  
This essay is based on the opening keynote for ISSOTL 2016: Telling the Stories of Teaching and Learning in Los Angeles, California.  ...  I argue that we should examine our unspoken assumptions about genre in SoTL and consider what elements of teaching and learning get left out because they are too hard to represent in our dominant genres  ...  Reading the stories of teaching and learning. Teaching & Learning Inquiry, 5(1). http://dx.doi.org/10.20343/teachlearninqu.5.1.13  ... 
doi:10.20343/teachlearninqu.5.1.13 fatcat:urkykucjzrbstdfvncwuonw26m

1 Keynote address by Nobel Laureate Phillip A. Sharp the 21st century opened with a revolution in RNA biology

Phillip A. Sharp
2015 Journal of Biomolecular Structure and Dynamics  
Excitingly, these insights and others are now being translated into new treatments for diseases and control of plant pathogens. 2 His Nobel Lecture and his speculative commentary on "What does the Future  ...  Long non-coding RNAs regulate the expression of genes through both cis and trans mechanisms and provide organization to the nucleus.  ...  We thank PEDECIBA QUÍMICA for the economic support, and Urimpex and Castel Pujol for the propolis and grape pomace samples respectively.  ... 
doi:10.1080/07391102.2015.1032624 fatcat:w7iil7k3ize77bjkthcyi52ohy

Keynote Speech: A Review of the Ontological Status, Computational Foundations and Methodological Processes of Agent-Based Modeling and Simulation Approaches: Open Challenges and Research Perspectives [chapter]

Alexis Drogoul
2008 Lecture Notes in Computer Science  
and credibility of ABMs, especially with respect to the last category of criticisms.  ...  This will give me the opportunity to underline which current and future directions of multiagent researches should be mobilized in order to provide innovative answers and therefore contribute to the reinforcement  ...  Ho, and Q.T. Ha (Eds.): PRIMA 2008, LNAI 5357, p. 1, 2008. c Springer-Verlag Berlin Heidelberg 2008  ... 
doi:10.1007/978-3-540-89674-6_1 fatcat:ztu6qjjcrvbetir2nznwofqqzy

470 A phase 1/2, open-label, dose escalation and expansion study of GI-101 as a single agent and in combination with a pembrolizumab, lenvatinib or local RT in advanced solid tumors (KEYNOTE-B59)

Byoung Chul Cho, Sang Joon Shin, Jae-Lyun Lee, Byoung Yong Shim, Hyung Soon Park, Nari Yun, Mina Ham, Young Jun Koh, Myoung Ho Jang
2021 Journal for ImmunoTherapy of Cancer  
GI-101 also elicited synergistic anti-tumor efficacy when used in combination with pembrolizumab (anti-PD1 agents), lenvatinib (tyrosine kinase inhibitor) and radiation in in vivo.1 Given the complementary  ...  with other immunotherapies, VEGF inhibitors or RT may exert anti-tumor activity in cancers with high unmet needs.MethodsKEYNOTE-B59 (NCT04977453) is an ongoing phase 1/2 study composed of 4 parts.  ...  Methods KEYNOTE-B59 (NCT04977453) is an ongoing phase 1/2 study composed of 4 parts. This study is planned to enroll approximately 374 patients across the indications.  ... 
doi:10.1136/jitc-2021-sitc2021.470 fatcat:rrw3dy27uvf3hlhgrxftl7ytom

Open Shape Morphing Honeycombs Through Kirigami

Robin M. Neville, Alberto Pirrera, Fabrizio Scarpa
2014 Volume 1: Development and Characterization of Multifunctional Materials; Modeling, Simulation and Control of Adaptive Systems; Structural Health Monitoring; Keynote Presentation   unpublished
This work presents an "open" and deployable honeycomb configuration created using kirigami-inspired cutting and folding techniques.  ...  The open honeycomb differs from traditional "closed" honeycomb by its reduced density and its increased flexibility.  ...  ) sin2 α +1 = 1 D sin 2 α+1 (16) where D=( b 2 2bl cosθ ) When α = 45º, sin2α = 1 and the relative density of the open configurations is at a minimum with a value of 1/(C+1) or 1/(D+1) depending on the  ... 
doi:10.1115/smasis2014-7489 fatcat:l4pxsqcihfefvjeoockd5eomka

Things + Ideas + Musealization = Heritage A Museological Approach 1 Keynote Speech delivered on 17 March 2008, at the opening of the Academic Year of the Graduate Program in Museology and Heritage-PPG-PMUS, UNIRIO/ MAST, Rio de Janeiro, Brazil

Martin Schärer
unpublished
The value and meaning can be different for individuals and for society, and these values can constantly change.  ...  and through their future demise through decay, wear-and-tear and/or destruction. Each "biographical" phase of an object is connected with either loss or a gain of information.  ... 
fatcat:tu5ixp2gmjgfpih6rsya5yz7e4

Keynote 42: Pembrolizumab, PD-L1, and where to draw the line

James Isaacs, Jeffrey Clarke, Neal Ready
2020 Annals of Translational Medicine  
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial  ...  While cross-trial comparisons are limited, response rate and overall survival at 1 year with combination therapy in Keynote 189 appear superior compared to pembrolizumab monotherapy in Keynote 42 (OS at  ...  Keynote 42 has established pembrolizumab monotherapy as an important new treatment option for patients with NSCLC PD-L1 TPS ≥1%, and clinicians can consider individual patient circumstances and preferences  ... 
doi:10.21037/atm.2020.01.65 pmid:32395561 pmcid:PMC7210198 fatcat:vfgpg26czzetlkgqbzsqfgmcym

Using Keynote to Present Radiology Images

Brian B. Ghoshhajra, Tust Techasith, Garry Choy, Carlos A. Rojas, Stuart R. Pomerantz
2010 Journal of digital imaging  
Lastly, it addresses the steps to converting between PowerPoint and Keynote file formats.  ...  Apple Macintosh (Cupertino, CA) computers are gaining popularity with many radiologists, due in part to the availability of a powerful, free, open-source Digital Imaging and Communications in Medicine  ...  Converting Between PowerPoint and Keynote Files Users transitioning between PowerPoint files and Keynote will find that PowerPoint files can be opened in Keynote (although minor adjustments may be necessary  ... 
doi:10.1007/s10278-010-9345-y pmid:20978920 pmcid:PMC3180549 fatcat:gs6zueieizhwfn5mi6j6anvecu

BOSC 2021, the 22nd Annual Bioinformatics Open Source Conference

Nomi L. Harris, Peter J. A. Cock, Christopher J. Fields, Karsten Hokamp, Jessica Maia, Monica Munoz-Torres, Malvika Sharan, Jason Williams
2021 F1000Research  
Launched in 2000 and held every year since, BOSC is the premier meeting covering topics related to open source software and open science in bioinformatics.  ...  Nearly 200 people participated in BOSC sessions, which included 27 talks reviewed and selected from submitted abstracts, and three invited keynote talks representing a range of global perspectives on the  ...  meeting expenses as well as offer speaker honoraria and free registration to 20 participants.  ... 
doi:10.12688/f1000research.74074.1 pmid:34721839 pmcid:PMC8524300 fatcat:metqcponazbl7cauyupds5t5yy

ALPACA 2022: First Workshop on Adaptive, Learning Pervasive Computing Applications - Program

2022 2022 IEEE International Conference on Pervasive Computing and Communications Workshops and other Affiliated Events (PerCom Workshops)  
Monday, March 21 1:00 pm-2:15 pm ALPACA_S1: ALPACA: Opening and Keynote 2:30 pm-3:30 pm ALPACA_S2: ALPACA: Session 1: Self-adaptation in IoT and Fog Computing 3:45 pm-4:45 pm ALPCAC_S3: ALPACA: Session  ...  Systems Rubén Rentero-Trejo, José García-Alonso, Juan Manuel Murillo Rodriguez and Javier Berrocal (University of Extremadura, Spain) Monday, March 21 1:00 -2:15 ALPACA_S1: ALPACA: Opening and Keynote  ... 
doi:10.1109/percomworkshops53856.2022.9767477 fatcat:idnsxzse4ngpfnbumdc52ol6xa

ESMO20 YO for YO: highlights on metastatic NSCLC-Keynote 024 update

E Mariamidze, L Mezquita
2021 ESMO Open  
Keynote-024 5-year overall survival (OS) update: first line Pembrolizumab versus platinum based chemotherapy in patients with metastatic NSCLC and programmed deathligand 1 (PD-L1) tumor proportion score  ...  REFERENCE 1. Brahmer JR.  ...  Keynote-024 5-year overall survival (OS) update: first line Pembrolizumab versus platinum based chemotherapy in patients with metastatic NSCLC and programmed deathligand 1 (PD-L1) tumor proportion score  ... 
doi:10.1016/j.esmoop.2020.100022 pmid:33399084 pmcid:PMC7808103 fatcat:jbpog6h5c5bipm5wknvp5l6hqi

Putting context into search and search into context

Susan T. Dumais
2012 Proceedings of the 35th international ACM SIGIR conference on Research and development in information retrieval - SIGIR '12  
Tennis Open 2012 …  Before event: Schedules and tickets, e.g., stubhub  During event: Real-time scores or broadcast, e.g., espn, cbssports  After event: General sites, e.g., wikipedia, usta Elsas &  ...  Teevan et al., ToCHI 2010 0.75 0.8 0.85 0.9 0.95 1 1.05 1 2 3 4 5 6 DCG Num ber of People Potential for Personalization Indivi… 0.75 0.8 0.85 0.9 0.95 1 1.05  ... 
doi:10.1145/2348283.2348447 dblp:conf/sigir/Dumais12 fatcat:vbuwsrlk4fcrpibwgoqot3eoxu

Immunotherapy in lung cancer: the chemotherapy conundrum

Laxmi Narayana R. Buddharaju, Apar Kishor Ganti
2020 Chinese Clinical Oncology  
performance status (ECOG 0-1) and a PD-L1 TPS of 1% or greater (5) .  ...  While the KEYNOTE-042 studied three different cohorts of patients with PD-L1 TPS of ≥1%, ≥20% and ≥50%, unfortunately they did not report the results of patients with TPS ≥1-49% separately.  ... 
doi:10.21037/cco.2020.01.05 pmid:32036674 fatcat:2emmms4irjd4remyscy4a7u73e
« Previous Showing results 1 — 15 out of 55,368 results